New study tracks psoriasis drug in kids: will it last?
NCT ID NCT06142357
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 28 times
Summary
This study follows about 200 children aged 6 to 17 with moderate-to-severe plaque psoriasis who are taking secukinumab. Researchers want to see how long patients stay on the drug and how well it controls their disease. The study does not test a new treatment but observes real-world use of an existing medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Chelyabinsk, 454048, Russia
-
Novartis Investigative Site
Grozny, 364022, Russia
-
Novartis Investigative Site
Izhevsk, 426009, Russia
-
Novartis Investigative Site
Kazan', 420012, Russia
-
Novartis Investigative Site
Kemerovo, 650025, Russia
-
Novartis Investigative Site
Moscow, 105007, Russia
-
Novartis Investigative Site
Moscow, 117513, Russia
-
Novartis Investigative Site
Moscow, 119296, Russia
-
Novartis Investigative Site
Moscow, 119435, Russia
-
Novartis Investigative Site
Mytishchi, 141009, Russia
-
Novartis Investigative Site
Nizhny Novgorod, 603950, Russia
-
Novartis Investigative Site
Rostov-on-Don, 344022, Russia
-
Novartis Investigative Site
Tolyatti, 445846, Russia
-
Novartis Investigative Site
Tula, 300053, Russia
-
Novartis Investigative Site
Ufa, 450000, Russia
-
Novartis Investigative Site
Yakutsk, 677000, Russia
Conditions
Explore the condition pages connected to this study.